Juvenile MyopiaCYPRESSNCT03623074
Control of Myopia Using Novel Spectacle Lens Designs
A study testing Novel spectacle lens design and Spectacle lenses in people with Juvenile Myopia, run by SightGlass Vision, Inc. at 14 sites in 2 countries.
Trial summary
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia. Read more about this study
- Who is it for?
- Ages 6 to 10 yearsHealthy volunteers can take part
- Conditions the study is for
- Juvenile Myopia
- What is being tested?
- Novel spectacle lens design and Spectacle lenses
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 266 participants
- Where
- 14 sitesin 2 countries
- Study dates
- 16 Jul 2018to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 10 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Children 6-10 years of age (day prior to 10th birthday) at time of informed consent/assent
- SER error between -0.75 and -4.50 D
- SER power between the two eyes must be less than or equal to 1.50 D
- Willingness to participate in the trial for 3 years without content lens wear
Who cannot join
- Previous or current use of contact lenses
- Previous or current use of bifocals, progressive addition spectacles lenses
- Previous or current use of myopia control treatment
- Astigmatism worse then -1.25 DC in either eye
Trial locations and contacts
14 sites in 2 countries.
14 sites in 2 countries
United States13 sites
Dunes Eye Consultants
Dakota Dunes, South Dakota, 57049
University of Houston College of Optometry
Houston, Texas, 77204
Sabal Eye Care
Longwood, Florida, 32779
Total Eye Care
Memphis, Tennessee, 38119
SUNY School of Optometry
New York, New York, 10036
Visual Performance Center
Pensacola, Florida, 32503
Kannarr Eye Care
Pittsburg, Kansas, 66762
Advanced Eyecare, PC
Raytown, Missouri, 64133
William J Bogus, OD, FAAO
Salt Lake City, Utah, 84106
Sacco Eye Group
Vestal, New York, 13850
Dept of Clinical Research, South Shore Eye Care, LLP
Wantagh, New York, 11793
Eye Associates of Northeast Louisiana (DBA Haik Humble Eye Center) Research Dept
West Monroe, Louisiana, 71291
Golden Optometric Group
Whittier, California, 90606
Canada1 site
Center for Ocular Research & Education, School of Optometry, University of Waterloo School of Optometry & Vision Science
Waterloo, Ontario, N2L 3G1
About this study
Official title: Efficacy and Safety Study of Novel Spectacle Lens Designs to Control of Myopia
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.
- Conditions
- Juvenile Myopia
- Being tested
- Novel spectacle lens design, Spectacle lenses
- Keywords
- Myopia
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Novel spectacle lens designDevice
Use of lenses may reduce the rate of progression of juvenile myopia
Spectacle lensesDevice
Use of lenses may reduce the rate of progression of juvenile myopia
| Study group | Role | What they receive |
|---|---|---|
| Test Arm 1 | Experimental | Single vision, impact-resistant spectacle lenses Receives: Device: Novel spectacle lens design |
| Test Arm 2 | Experimental | Single vision, impact-resistant spectacle lenses Receives: Device: Novel spectacle lens design |
| Test Arm 3 | Other | Single vision, impact-resistant spectacle lenses Receives: Device: Spectacle lenses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Axial length
Change in axial length from baseline
Measured: 36 Months
Spherical equivalent refraction
Change in spherical equivalent refraction from baseline
Measured: 36 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2018
- Study start16 Jul 2018
- Primary completion15 May 2022
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Juvenile MyopiaStudies of the same condition, open and under way.
- More trials run by SightGlass Vision, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 266 participants (actual)
Sponsor and investigators
- Lead sponsor
- SightGlass Vision, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Joseph Rappon, OD, MS, FAAO, Study chair, SightGlass Vision, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03623074
- Sponsor's protocol ID
- CPRO-1802-001
- Acronym
- CYPRESS
- Status last verified
- Apr 2026
- First submitted
- 3 Aug 2018
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Laughton D, Hill JS, McParland M, Tasso V, Woods J, Zhu X, Young G, Craven R, Hunt C, Neitz J, Neitz M, Chalberg TW, Jones D, Wolffsohn JS. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS). BMJ Open Ophthalmol. 2024 Oct 9;9(1):e001790. doi: 10.1136/bmjophth-2024-001790.
PubMed 39384223Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M, Chalberg T. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov;107(11):1709-1715. doi: 10.1136/bjo-2021-321005. Epub 2022 Sep 1.
PubMed 36126105
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety Study of Novel Spectacle Lens Designs to Control of Myopia
- ClinicalTrials.gov ID
- NCT03623074
- Acronym / sponsor ID
- CYPRESS / CPRO-1802-001
- Conditions
- Juvenile Myopia
- Keywords
- Myopia
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 266 participants (actual)
- Lead sponsor
- SightGlass Vision, Inc.Industry (pharma, biotech, devices)
- Study start
- 16 Jul 2018 (actual)
- Primary completion
- 15 May 2022 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 9 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Test Arm 1 | Experimental | Device: Novel spectacle lens designSingle vision, impact-resistant spectacle lenses |
| Test Arm 2 | Experimental | Device: Novel spectacle lens designSingle vision, impact-resistant spectacle lenses |
| Test Arm 3 | Other | Device: Spectacle lensesSingle vision, impact-resistant spectacle lenses |
Who may qualify
- Ages
- 6 to 10 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children 6-10 years of age (day prior to 10th birthday) at time of informed consent/assent
- SER error between -0.75 and -4.50 D
- SER power between the two eyes must be less than or equal to 1.50 D
- Willingness to participate in the trial for 3 years without content lens wear
Key exclusion criteria (4 listed)
- Previous or current use of contact lenses
- Previous or current use of bifocals, progressive addition spectacles lenses
- Previous or current use of myopia control treatment
- Astigmatism worse then -1.25 DC in either eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Novel spectacle lens designUse of lenses may reduce the rate of progression of juvenile myopia | Device | Test Arm 1, Test Arm 2 |
| Spectacle lensesUse of lenses may reduce the rate of progression of juvenile myopia | Device | Test Arm 3 |
Primary outcome
Axial length
Time frame: 36 Months
Change in axial length from baseline
Spherical equivalent refraction
Time frame: 36 Months
Change in spherical equivalent refraction from baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Derived from this study: PubMed 39384223Laughton D, Hill JS, McParland M, Tasso V, Woods J, Zhu X, Young G, Craven R, Hunt C, Neitz J, Neitz M, Chalberg TW, Jones D, Wolffsohn JS. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS). BMJ Open Ophthalmol. 2024 Oct 9;9(1):e001790. doi: 10.1136/bmjophth-2024-001790.
- Derived from this study: PubMed 36126105Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M, Chalberg T. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov;107(11):1709-1715. doi: 10.1136/bjo-2021-321005. Epub 2022 Sep 1.
Related trials for Juvenile Myopia
Recruiting
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
Myopia, Myopia Progression
Recruiting
Children's Viewing Behavior
Myopia, Myopia Progression
Active, not recruiting
Assessment of DOT Spectacles in Chinese Children
Juvenile Myopia, Myopia
Active, not recruiting
Myopia Control Spectacle Lens Cessation Study
Myopia, Myopia Progression
Active, not recruiting
Spectacle Lens Visual Acuity Assessments Study
Myopia, Myopia Progression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joseph Rappon, OD, MS, FAAO study chair
SightGlass Vision, Inc.
14 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Novel spectacle lens design and Spectacle lenses in people with Juvenile Myopia, run by SightGlass Vision, Inc. at 14 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Axial length (time frame: 36 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03623074, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.